SunTrust analyst Peter Dawson notes yesterday's speculation in Intereconomia.com about a potential acquisition of Tesaro (TSRO) by Roche (RHHBY), saying his M&A valuation analysis puts a potential takeout value on Tesare at $153 per share or about $8.4B. The analyst says the rumor is also positive for other PARP inhibitor players like Clovis (CLVS) as well as Tesaro's oncology peers. Dawson keeps his Buy rating and $150 price target on Tesaro stock.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Alecensa for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor. "With an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, Alecensa significantly improves upon the standard of care for people with early-stage ALK-positive lung cancer," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "At Genentech, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease before their cancer has spread. This approval brings us one step closer to achieving that mission."